KQT2 Inhibitors
KQT2 inhibitors are chemical compounds that target the Kv7.2/Kv7.3 potassium channels, also referred to as the KQT2 channels. These channels are part of a broader family of voltage-gated potassium channels that play a critical role in regulating the electrical excitability of neurons and other excitable cells. KQT2 channels specifically help control the flow of potassium ions across cell membranes, influencing the cell's membrane potential and the ability to generate action potentials. Inhibitors of KQT2 act by blocking or reducing the activity of these channels, altering the flow of potassium ions and affecting the overall electrical properties of the cells in which these channels are expressed. This modulation can lead to changes in cellular excitability, influencing the way that cells respond to stimuli.
Structurally, KQT2 inhibitors are often designed to interact with specific sites within the Kv7.2/Kv7.3 channels, typically through mechanisms that involve binding to the channel's pore or voltage-sensing domains. These interactions can stabilize specific conformations of the channel, preventing it from opening or promoting its closed state. The precise molecular architecture of KQT2 inhibitors can vary widely, and these compounds may feature diverse chemical backbones and functional groups that provide selective affinity for the KQT2 channel subtypes. Modulation of KQT2 channels by these inhibitors is of significant interest in research focused on understanding cellular electrophysiology, as these channels are key contributors to maintaining the balance of ion flows in excitable tissues such as the brain and heart.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
By inhibiting DNA methyltransferase, 5-Azacytidine could promote demethylation of the KCNQ2 gene promoter, potentially leading to its transcriptional downregulation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A may disrupt histone acetylation patterns, potentially leading to a condensed chromatin conformation that decreases KCNQ2 gene expression. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $85.00 | 9 | |
Valproic Acid may alter the chromatin structure surrounding the KCNQ2 gene by inhibiting histone deacetylase, which could result in decreased expression of this gene. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin could inhibit the mTOR pathway, which may lead to a reduction in the cap-dependent translation process, possibly reducing the synthesis of the KCNQ2 protein. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D could intercalate into DNA and inhibit RNA polymerase movement along the DNA, which would decrease transcription of multiple genes including KCNQ2. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $260.00 $1029.00 | 26 | |
α-Amanitin may inhibit RNA polymerase II, leading to a significant decrease in the transcription of RNA coding for the KCNQ2 channel. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $42.00 $185.00 $310.00 $650.00 | 6 | |
DRB could inhibit the phosphorylation of RNA polymerase II, resulting in transcriptional elongation arrest and subsequent reduction in KCNQ2 expression. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
As a cyclin-dependent kinase inhibitor, Flavopiridol might lead to the arrest of cell cycle progression, which could decrease expression levels of cell cycle-regulated genes, potentially including KCNQ2. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1 could competitively inhibit the binding of BET bromodomain proteins to acetylated histones, potentially leading to the downregulation of BET protein-regulated genes, such as KCNQ2. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Geldanamycin binds to Hsp90 and inhibits its function, which could lead to the destabilization of several signaling proteins and a subsequent decrease in transcriptional activity, potentially inhibiting KCNQ2 expression. | ||||||